

Table S1. Effect of dose reduction scenarios on patients with predicted neuropathy score ≥ 8 at C7D1, stratified by C4D1 neuropathy scores (paclitaxel).

Scenario	% Dose reduction in each cycle compared to Cycle 3 dose (total % dose reduction)	Paclitaxel			
		Percent of patients with neuropathy Score ≥ 8 at C7D1			
		C4D1 neuropathy Score < 4 (Category 1)	C4D1 neuropathy Score 4-7 (Category 2)	C4D1 neuropathy Score 8-9 (Category 3)	C4D1 neuropathy Score ≥ 10 (Category 4)
No dose reduction	0%	0	100 (23/23)	100 (14/14)	100 (14/14)
Scenario 1: Reduction	10%	0	87 (20/23)	100 (14/14)	100 (14/14)
	20%	0	57 (13/23)	79 (11/14)	100 (14/14)
	30%	0	13 (3/23)	57 (8/14)	100 (14/14)
	40%	0	4 (1/23)	50 (7/14)	100 (14/14)
	50%	0	0	36 (5/14)	86 (12/14)
Scenario 2: Skip day 8 +/- reduction	Skip day 8 (33%)	0	13 (3/23)	50 (7/14)	100 (14/14)
	Skip day 8 + 10% dose reduction (40%)	0	4 (1/23)	50 (7/14)	100 (14/14)
	Skip day 8 + 20% dose reduction (47%)	0	0	36 (5/14)	86 (12/14)
	Skip day 8 + 30% dose reduction (53%)	0	0	21 (3/14)	71 (10/14)
	Skip day 8 + 40% dose reduction (60%)	0	0	7 (1/14)	57 (8/14)
	Skip day 8 + 50% dose reduction (67%)	0	0	0	50 (7/14)
Scenario 3: Skip C4 +/- reduction	Skip C4 doses (33%#)	0	13 (3/23)	71 (10/14)	100 (14/14)
	Skip C4 doses + 10% dose reduction (40%)	0	4 (1/23)	64 (9/14)	100 (14/14)
	Skip C4 doses + 20% dose reduction (47%)	0	0	57 (8/14)	100 (14/14)
	Skip C4 doses + 30% dose reduction (53%)	0	0	29 (4/14)	93 (13/14)
	Skip C4 doses + 40% dose reduction (60%)	0	0	7 (1/14)	79 (11/14)
	Skip C4 doses + 50% dose reduction (67%)	0	0	0	43 (6/14)

The total number of patients with predicted neuropathy score ≥ 8 at C7D1 were 23/45 (51%), 14/14 (100%), 14/14 (100%) in categories 2, 3 and 4, respectively.

Table S2. Effect of dose reduction scenarios on patients with predicted neuropathy score ≥ 8 at C7D1, stratified by C4D1 neuropathy scores (nab-paclitaxel)

Scenario	% Dose reduction in each cycle compared to Cycle 3 dose (total % dose reduction)	Nab-paclitaxel			
		Percent of patients with neuropathy Score ≥ 8 at C7D1			
		C4D1 neuropathy Score < 4 (Category 1)	C4D1 neuropathy Score 4-7 (Category 2)	C4D1 neuropathy Score 8-9 (Category 3)	C4D1 neuropathy Score ≥ 10 (Category 4)
No dose reduction	0%	100 (2/2)	100 (26/26)	100 (13/13)	100 (17/17)
Scenario 1: Reduction	10%	0	77 (20/26)	100 (13/13)	100 (17/17)
	20%	0	58 (15/26)	92 (12/13)	100 (17/17)
	30%	0	35 (9/26)	77 (10/13)	88 (15/17)
	40%	0	27 (7/26)	77 (10/13)	76 (13/17)
	50%	0	19 (5/26)	69 (9/13)	76 (13/17)
Scenario 2: Skip day 8 +/- reduction	Skip day 8 (33%)	0	35 (9/26)	77 (10/13)	88 (15/17)
	Skip day 8 + 10% dose reduction (40%)	0	27 (7/26)	77 (10/13)	76 (13/17)
	Skip day 8 + 20% dose reduction (47%)	0	23 (6/26)	77 (10/13)	76 (13/17)
	Skip day 8 + 30% dose reduction (53%)	0	15 (4/26)	62 (8/13)	76 (13/17)
	Skip day 8 + 40% dose reduction (60%)	0	12 (3/26)	46 (6/13)	76 (13/17)
	Skip day 8 + 50% dose reduction (67%)	0	8 (2/26)	31 (4/13)	65 (11/17)
Scenario 3: Skip C4 +/- reduction	Skip C4 doses (33%#)	0	35 (9/26)	92 (12/13)	100 (17/17)
	Skip C4 doses + 10% dose reduction (40%)	0	27 (7/26)	85 (11/13)	100 (17/17)
	Skip C4 doses + 20% dose reduction (47%)	0	19 (5/26)	69 (9/13)	94 (16/17)
	Skip C4 doses + 30% dose reduction (53%)	0	15 (4/26)	62 (8/13)	76 (13/17)
	Skip C4 doses + 40% dose reduction (60%)	0	12 (3/26)	54 (7/13)	76 (13/17)
	Skip C4 doses + 50% dose reduction (67%)	0	8 (2/26)	31 (4/13)	76 (13/17)

The total number of patients with predicted neuropathy score ≥ 8 at C7D1 were 2/68 (3%), 26/48 (54%), 13/13 (100%), 17/17 (100%) in categories 1, 2, 3 and 4, respectively.

Table S3. Effect of dose reduction scenarios on patients with predicted neuropathy score ≥ 8 at C7D1, stratified by C4D1 neuropathy scores (ixabepilone).

Scenario	% Dose reduction in each cycle compared to Cycle 3 dose (total % dose reduction)	Ixabepilone			
		Percent of patients with neuropathy Score ≥ 8 at C7D1			
		C4D1 neuropathy Score <4 (Category 1)	C4D1 neuropathy Score 4-7 (Category 2)	C4D1 neuropathy Score 8-9 (Category 3)	C4D1 neuropathy Score ≥ 10 (Category 4)
No dose reduction	0%	100 (3/3)	100 (24/24)	100 (6/6)	100 (10/10)
Scenario 1: Reduction	10%	100 (3/3)	100 (24/24)	100 (6/6)	100 (10/10)
	20%	100 (3/3)	88 (21/24)	100 (6/6)	100 (10/10)
	30%	33 (1/3)	75 (18/24)	100 (6/6)	100 (10/10)
	40%	0	63 (15/24)	100 (6/6)	90 (9/10)
	50%	0	54 (13/24)	83 (5/6)	90 (9/10)
Scenario 2: Skip day 8 +/- reduction	Skip day 8 (33%)	0	71 (17/24)	100 (6/6)	100 (10/10)
	Skip day 8 + 10% dose reduction (40%)	0	63 (15/24)	100 (6/6)	90 (9/10)
	Skip day 8 + 20% dose reduction (47%)	0	54 (13/24)	100 (6/6)	90 (9/10)
	Skip day 8 + 30% dose reduction (53%)	0	54 (13/24)	83 (5/6)	90 (9/10)
	Skip day 8 + 40% dose reduction (60%)	0	42 (10/24)	83 (5/6)	90 (9/10)
	Skip day 8 + 50% dose reduction (67%)	0	38 (9/24)	83 (5/6)	80 (8/10)
Scenario 3: Skip C4 +/- reduction	Skip C4 doses (33%#)	0	67 (16/24)	100 (6/6)	100 (10/10)
	Skip C4 doses + 10% dose reduction (40%)	0	54 (13/24)	100 (6/6)	100 (10/10)
	Skip C4 doses + 20% dose reduction (47%)	0	54 (13/24)	100 (6/6)	100 (10/10)
	Skip C4 doses + 30% dose reduction (53%)	0	46 (11/24)	83 (5/6)	90 (9/10)
	Skip C4 doses + 40% dose reduction (60%)	0	42 (10/24)	83 (5/6)	90 (9/10)
	Skip C4 doses + 50% dose reduction (67%)	0	29 (7/24)	83 (5/6)	90 (9/10)

The total number of patients with predicted neuropathy score ≥ 8 at C7D1 were 3/90 (3%), 24/26 (92%), 6/6 (100%), 10/10 (100%) in categories 1, 2, 3 and 4, respectively.

